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Background. Mounting evidence suggests an association between human papillomavirus (HPV) and HIV acquisition. This study
aimed to explore this association among South African female sex workers (FSWs). Methods.W eu s e dd a t af r o m8 8H I V - n e g a t i v e
FSWs who participated in a vaginal gel (COL-1492) trial. Cervicovaginal rinse samples, obtained before HIV-seroconversion, were
genotyped into high-risk (HR-) and low-risk (LR-) HPV. HIV-adjusted hazard ratios (aHRs) and 95% conﬁdence intervals (CI)
were estimated using Cox survival analysis. Results. HR- and LR-HPV prevalences were 70.5% (95% CI:60.5–79.2) and 60.2%
(95% CI:49.9–70.0), respectively. Twenty-ﬁve women HIV seroconverted. Controlling for background characteristics and other
sexually transmitted infections, HIV aHR increased by a factor of 1.7 (95% CI:1.01–2.7, Plinear trend = 0.045) for an increase of
one unit of the number of HR-HPV genotypes. Conclusions. HIV seroconversion among FSWs is associated with genital HR-HPV
infection. Further investigation is warranted, including testing the possible protective eﬀect of available HPV vaccines on HIV
acquisition.
1.Background
HIV prevalence in South Africa is one of the highest in
the world, with over 17% of adults infected with HIV
[1]. Women are a particularly vulnerable group, with HIV
prevalence and incidence far exceeding that of men from the
regionandofwomeninotherpartsoftheworld[2].InSouth
Africa, 90% of new infections in the 15 to 24 age group are
among women[3], andHIV prevalencesof upto66.7% have
been reported among women aged 24 [4].
A number of sexually transmitted infections (STIs),
notably HSV-2, have been identiﬁed as key biomedical risk
factors for the heterosexual transmission of HIV [2, 5, 6].
Among high-risk populations, female sex-workers (FSWs)
generally have disproportionately high rates of STIs [7], and
are likely to be at increased risk of HIV exposure. In low-
income settings where condom use is inconsistent and access
to eﬀective STI treatment limited, an estimated 50 to 75% of
FSWs are infected with at least one STI at any one time, and
multiple infections are common [7].
In recent years, the association between HIV and genital
human papillomavirus (HPV), one of the most common STI
worldwide, has generated much interest. In South Africa,
genital HPV is thought to aﬀect about 21.0% of women with
normal cytology [8], and HPV prevalence among FSWs is
estimated to be two and a half to four times higher [9].
Genital HPV genotypes are divided into “high-risk” (HR)
and “low-risk” (LR) types on the basis of their association
with malignancies of the cervix. HR-HPV is a signiﬁcant
cause of morbidity and mortality in South Africa due to its2 Infectious Diseases in Obstetrics and Gynecology
aetiological association with genital cancer [10–15], cervical
carcinoma being the second leading cause of cancer death
among South African women [8].
Mounting evidence suggests an association between
HPV serostatus and HIV infection. Several studies con-
ducted among sub-Saharan African women indicate that
HIV seropositivity is strongly associated with higher HPV
prevalence [14, 16–23], higher HR-HPV prevalence [16, 17,
19],higherHPVincidence[20],areducedlikelihoodofHPV
infectionclearance,whichisassociatedwithanincreasedrisk
of HPV-related lesions [20, 23, 24], and higher prevalence of
infection with multiple HPV genotypes [14, 16, 17, 19, 21,
23,24].Furthermore,HIVseropositivityhasalsobeenfound
to be associated with the development of high-grade cervical
squamous intraepithelial lesions [25], the presence of high
andlow-gradecervicalsquamousintraepitheliallesions[22],
as well as invasive cervical carcinoma, a recognised AIDS-
deﬁning condition [19, 26] and the most common cancer
among HIV-positive women in sub-Saharan Africa [27].
More recently, an association between HPV infection
and HIV acquisition has been suggested, but to date, only
few studies have been conducted among women to test this
hypothesis [28–30]. The objective of this study was to assess
HPV as a risk factor of HIV acquisition among FSWs in
South Africa, a group which is presumably at high risk for
STIs such as HPV and HIV.
2. Methods
2.1. Study Population and Sample Collection. Data were
obtained from South African FSWs from the Kwazulu-Natal
Midlands, who were participating in a multicentre, ran-
domised, placebo-controlled, triple-blinded, phase 2/3 eﬃ-
cacytrialofCOL-1492,alow-dosenonoxynol-9microbicide.
The trial was funded by the United Nations Programme on
HIV/AIDS (UNAIDS), and conducted between September
1996 and June 2000.
In brief, 187 healthy, nondrug using, not pregnant, HIV-
negative South African FSWs were recruited by the Medical
Research Council of Durban from truck stops along the
major highway between the port city of Durban and the
commercialcapitalJohannesburgandenrolledinthetrial.At
the screening visit, comprehensive information on the trial
was provided and written informed consent was obtained.
Participants were randomly assigned to a nonoxynol-9
containing gel (COL-1492) or the same placebo gel without
nonoxynol-9. Data on demographics, background charac-
teristics and sexual behaviour were collected at baseline.
The primary endpoint was incident HIV-1 infection. The
retention rate in the study at 48 weeks was 88%. Due to
issueswithprocessing,HPVsampledatawereunavailablefor
83 women, but their baseline characteristics did not diﬀer
signiﬁcantly from those of the remaining 104 women [31].
Details on the trial have been published elsewhere [31, 32].
Samples used for the present study were cervicovaginal
rinses(CVRs),whichwerecollectedandtestedforHPV.The-
ses samples were obtained at baseline, which started in 1996,
in December 1998 (Followup A) and in December 1999
(Followup B). The full follow-up schedule of the study
participants has been previously described [32, 33]. Full sets
of HPV samples (i.e., one sample collected at each time
point) were not obtained for all participants, some of whom
having missing data. Infection statuses at baseline for Tri-
chomonas vaginalis, Candida albicans, Neisseria gonorrhoeae,
Chlamydia trachomatis, and syphilis were also obtained as
described elsewhere [32].
In the current study, we included the 88 women who had
at least one HPV result, obtained before HIV conversion for
those who seroconverted.
2.2. Laboratory Testing. The detailed testing procedures have
been previously described [31, 32].
HIV testing was performed with sensitive antibody
ELISA (Abbott, Chicago, Ill, USA and Omnimed, UK)
and conﬁrmed by line immunoassay (Innogenetics, Ghent,
Belgium). Seroconversion dates were established using p24
antigen detection ELISA and a DNA PCR assay.
HPV DNA was extracted from the collected cervical cells
using a Qiagen DNA mini kit (Qiagen, Calif, USA). HPV
typing was performed with a reverse line blot assay (Roche
Molecular Systems, Calif), according to a published method
[34]. This assay could detect 13 HR-HPV genotypes (16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), 14 LR-
HPV genotypes (6, 11, 26, 40, 42, 53, 54, 55, 57, 66, 73, 82,
83, and 84) and had probes for internal β globin control.
As recommended by the manufacturer, β globin negative
samples were not included in the analysis [35]. Samples
were tested blinded of other study data. For quality control
procedures, PCR controls for the HPV genotyping test were
run together with test specimens in both the ampliﬁcation
and detection step of the assay.
Laboratory testing procedures for other STIs have
been previously described [32] and are available at http://
image.thelancet.com/extra/02art3365webmethods.pdf.
2.3. Statistical Analyses. HIV-adjusted hazard ratios (aHRs)
and 95% conﬁdence intervals (CIs) were estimated with
survival analysis (Cox model), using as covariates the follow-
ing baseline characteristics: number of HR-HPV genotypes
(referred to as number of HR-HPV in the text), number
of LR-HPV genotypes (referred to as number of LR-HPV
in the text), age (less than 24 years, 24 years, or more),
intervention group (placebo or Nonoxynol-9), condom
use (never, sometimes, or often), anal sex (yes or no),
length of sex work (less than 24 months, 24 or more),
number of clients per week (less than 20, 20 or more) and
status of other STI (Trichomonas vaginalis, Candida albicans,
Neisseria gonorrhoeae, Chlamydia trachomatis, and syphilis).
The variables age, length of sex work, and number of clients
were dichotomized based on their respective median values.
Because infections with HR-HPV and LR-HPV were
correlated (P = 0.007, Spearman’s rho test), the eﬀect of
LR-HPV on HIV incidence was ﬁrst tested by controlling for
HR-HPV. Similarly, the eﬀect of HR-HPV on HIV incidence
was ﬁrst tested by controlling for LR-HPV.Infectious Diseases in Obstetrics and Gynecology 3
TheCIsofthepercentageswerecalculatedusingBayesian
estimation [36]. Continuous variables and dichotomous
variables were compared using the Kruskal-Wallis test and
Fisher’s exact test, respectively. Statistical analyses were
performed using the statistical package SPSS for Windows
version 8 (SPSS, Chicago, Ill, USA).
3. Results
3.1. Background Characteristics. Median age of the partici-
pants was 24 (min–max: 19–45; interquartile range (IQR):
19 to 30). Participants had been engaging in sex work for
a median duration of 2.0 years (min–max: 0.17–23; IQR:
1.6 to 3.0), and their median number of clients per week
was 20 (min–max: 5–35; IQR: 11 to 25). Median duration
of participation in the study was 2.5 years (IQR: 1.7 to
2.8). Other background characteristics and STI status are
indicated in Table 1.
3.2. HPV Infection and Genotype Distribution. For the anal-
yses, we used the ﬁrst available HPV testing, which was
obtained at screening for 33 women (37.5%; 33/88), in
December 1998 for 44 women (50.0%, 44/88) for whom
HPV data at screening were unavailable, and in December
1999 for 11 women (12.5%; 11/88) for whom HPV data were
unavailableatscreeningandinDecember1998.TheHR-and
LR-HPV prevalences were 70.5% (62/88, 95% CI: 60.5–79.2)
and 60.2% (53/88, 95% CI: 49.9–70.0), respectively.
The distribution of the numbers of HR-HPV and LR-
HPVisshowninTable 2.Amongthe62womeninfectedwith
at least one HR-HPV, 102 diﬀerent HR-HPV genotypes were
detected. The distribution of these genotypes is illustrated
in Figure 1. This ﬁgure shows that among the 13 high-risk
genotypes detected, HR-HPV 18 was the most common.
HR-HPV 16 and HR-HPV 18 together represented close to
one third of all HR-HPV genotypes detected among the
participants.
3.3.HIVAcquisitionandRiskFactors. Amongthe88women,
28.4% (25/88) HIV seroconverted during followup. When
controlling for the number of HR-HPV, the number of LR-
HPV was not a risk factor for HIV acquisition (aHR = 0.95,
95% CI: 0.68–1.3, Plinear trend = 0.76). In contrast, when
controlling for the number of LR-HPV, the number of HR-
HPV was a risk factor for HIV acquisition (aHR = 1.6,
95% CI: 1.1–2.2, Plinear trend = 0.019). When assessing HIV
acquisition as a function of the total number of genotypes,
regardless of type, the univariate eﬀect was HR=1.2 (95% CI:
0.97–1.4; P = 0.089), and the multivariate eﬀect was aHR =
1.1 (95% CI: 0.84–1.4; P = 0.51).
The mean (median) duration in years of followup before
HIV infection was 2.4 (2.7) for women not infected with
HR-HPV and 2.2 (2.5) for those infected with at least one
HR-HPV genotype. The eﬀect of HR-HPV status and other
covariates on HIV acquisition, and the distribution of HIV
cases, are indicated in Table 1. In the multivariate analysis,
HIV acquisition signiﬁcantly increased with the number of
HR-HPV genotypes and level of education, and signiﬁcantly
Frequency of multiple infections:
HPV-16: 7/9
HPV-18: 12/22
HPV-31: 5/5
HPV-33: 1/1
HPV-35: 1/1
HPV-39: 9/9
HPV-45: 5/6
HPV-51: 8/10
HPV-52: 8/9
HPV-56: 3/3
HPV-58: 8/8
HPV-59: 0/1
HPV-68: 11/18
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Figure 1: Distribution of the 102 high-risk human papillomavirus
(HR-HPV) genotypes identiﬁed in the sample and frequency of
multiple infections per HR-HPV genotype.
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Figure 2: Kaplan-Meier HIV-free survival estimates for women
with0,1,2,3-4,andatleast1(1+)high-riskhumanpapillomavirus
genotypes.
decreased with age. Women infected with two or more HR-
HPV genotypes were at higher risk of acquiring HIV than
those infected with zero or one HR-HPV genotype (aHR =
4.0, 95% CI: 1.2–14.0, P = 0.028).
As shown in Figure 2,H I V - f r e es u r v i v a ld e c r e a s e dw i t h
the number of HR-HPV genotypes.
A sensitivity analysis was conducted to examine the
eﬀect of HR-HPV on HIV acquisition among women in the
placebo group. The univariate eﬀect was HR=1.9 (95% CI:
1.1–3.3, P = 0.027). The corresponding multivariate analysis
only included covariates having a univariate P value lower4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Distribution of detected HIV cases and risk factors of HIV acquisition.
Factor Distribution Number of HIV
infections Mean survival (days) Univariate HR
(95% CI)
Multivariate aHR∗
(95% CI)
Number of high-risk
HPV
0 29.5% (26/88) 5 1148
1 43.2% (38/88) 9 1110 1.5 (1.1 to 2.1)
P = 0.016
∗∗
1.7 (1.01 to 2.7)
P = 0.045
∗∗
2 14.8% (13/88) 5 934
3-4 12.5% (11/88) 6 775
Number of low-risk
HPV
0 39.8% (35/88) 7 1134
1 35.2% (31/88) 11 992 1.1 (0.12 to 0.69)
P = 0.70
∗∗
0.77 (0.49 to 1.2)
P = 0.26
∗∗
2 15.9% (14/88) 5 932
3 9.1 (8/88) 2 1136
Age (years)
Less than 24 46.6% (41/88) 18 933 1 1
24 or more 53.4% (47/88) 7 1192 0.29 (0.12 to 0.69)
P = 0.005
0.28 (0.079 to 0.97)
P = 0.044
Intervention
Placebo 46.6% (41/88) 9 1132 1 1
Nonoxynol-9 53.4% (47/88) 16 1013 1.8 (0.81 to 4.2)
P = 0.15
2.0 (0.75 to 5.1)
P = 0.17
Education
Less than 6 years 40.9% (36/88) 6 1184 1 1
6 years or more 59.1% (52/88) 19 990 2.7 (1.1 to 6.8)
P = 0.033
5.5 (1.6 to 19.6)
P = 0.0082
Condom use
Never or
sometimes 80.7% (71/88) 22 1044 1 1
Often 19.3% (17/88) 3 1175 0.57 (0.17 to 1.9)
P = 0.36
0.29 (0.05 to 1.6)
P = 0.16
Anal sex
No 56.8% (50/88) 18 1029 1 1
Yes 43.2% (38/88) 7 1137 0.53 (0.22 to 1.3)
P = 0.16
0.35 (0.12 to 1.0)
P = 0.052
Length of sex work
(months)
Less than 24 50.0% (44/88) 13 1045 1 1
24 or more 50.0% (44/88) 12 1091 0.89 (0.41 to 1.9)
P = 0.77
1.5 (0.41 to 5.6)
P = 0.53
Number of clients per
week
Less than 20 46.6% (41/88) 13 1056 1 1
20 or more 53.4% (47/88) 12 1076 0.78 (0.36 to 1.7)
P = 0.54
1.4 (0.48 to 3.9)
P = 0.56
Trichomonas vaginalis
Negative 64.2% (52/81) 17 1030 1 1
Positive 35.8% (29/81) 6 1109 0.52 (0.21 to 1.3)
P = 0.17
1.4 (0.41 to 4.6)
P = 0.61
Candida albicans
Negative 63.0% (51/81) 16 1038 1 1Infectious Diseases in Obstetrics and Gynecology 5
Table 1: Continued.
Factor Distribution Number of HIV
infections Mean survival (days) Univariate HR
(95% CI)
Multivariate aHR∗
(95% CI)
Positive 37.0% (30/81) 7 1129 0.67 (0.28 to 1.6)
P = 0.38
0.55 (0.18 to 1.7)
P = 0.29
Neisseria gonorrhoeae
Negative 91.3% (73/80) 20 1074 1 1
Positive 8.8% (7/80) 3 1065 1.33 (0.40 to 4.5)
P = 0.54
2.3 (0.53 to 9.6)
P = 0.27
Chlamydiatrachomatis
Negative 86.5% (64/74) 20 1039 1 1
Positive 13.5% (10/74) 7 1120 0.77 (0.23 to 2.6)
P = 0.67
0.25 (0.06 to 1.1)
P = 0.070
Syphilis
Negative 73.2% (60/82) 20 1042 1 1
Positive 26.8% (22/82) 4 1138 0.50 (0.17 to 1.5)
P = 0.21
0.66 (0.17 to 2.6)
P = 0.55
(a) HR: (adjusted) hazard ratio.
HPV: human papillomavirus.
∗The following variables were included in the multivariate analysis: number of high-risk HPV, number of low-risk HPV, age, intervention group, education,
condom use, anal sex, length of sex work, number of clients per week, infection with Trichomonas vaginalis, infection with Candida albicans, infection with
Neisseria gonorrhoea, infection with Chlamydia trachomatis, and infection with syphilis.
∗∗Increase of hazard ratio of HIV acquisition for an increase of one unit of the number of HPV. The P value corresponds to a linear trend.
Table 2: Distribution of the number of human papillomavirus (HPV) genotypes among HIV-negative women.
Number of high-risk
HPV genotypes
Percentage of women
(95% CI) [n]
Number of low-risk
HPV genotypes
Percentage of women
(95% CI) [n]
0 29.5 (20.8–39.5) [26] 0 39.8 (30.0–50.1) [35]
1 43.2 (33.2–53.5) [38] 1 35.2 (25.8–45.4) [31]
2 14.8 (8.4–23.1) [13] 2 15.9 (9.3–24.4) [14]
3 10.2 (5.1–17.7) [9] 3 3.4 (0.84–8.7) [3]
4 2.3 (0.36–7.0) [2] 4 5.7 (2.1–11.9) [5]
1–4 70.5 (60.5–79.2) [62] 1–4 60.2 (49.9–70.0) [53]
Total 100 [88] Total 100 [88]
than0.15(ageandeducation)becauseofthesmallernumber
of HIV infections and yielded an eﬀect aHR = 1.8 (95% CI:
1.0–3.3, P = 0.041).
3.4. Estimation of Potential Biases. Using the ﬁrst available
HPV testing result for our analysis may have been a source of
bias because in doing so, it was assumed that HPV status at
baseline and at the two follow-up visits were equivalent. This
is not necessarily correct, because the observed association
between HPV and HIV acquisition could be time dependent
due to the transient nature of HPV infection. To address
this issue, it was recommended that the analyses be repeated
taking time zero as the date of the ﬁrst HPV test. Although
this approach reduced the power of the analysis because it
reduced the total length of followup, the multivariate eﬀect
obtained (aHR = 1.6; 95% CI: 0.97 to 2.6; P = 0.067) was
very close to the reported estimate from the main analysis.
The 16 (104 minus 88) women who were excluded due to
lack of HPV results were compared with the 88 remaining
women in terms of background characteristics and STI
status, which are listed, Table 1. They did not diﬀer with
respect to their average age (26.6 versus 25.8; P = 0.54),
percentage having been randomized to the intervention
group (50.0% versus 46.6%; P = 1.0), percentage with at
least six years of education (81.3% versus 59.1%; P = 0.16),
percentage using condoms often (31.3% versus 19.3%; P =
0.32), percentage practicing anal sex (43.8% versus 43.2%;
P = 1.0), average duration of sex work in months (27.0
versus 34.9; P = 0.59), average number of clients per week
(21.4 versus 18.7; P = 0.26), prevalence of Trichomonas
vaginalis (18.8% versus 35.8%; P = 0.25), prevalence of
Candidaalbicans(50.0%versus37.0%;P = 0.40),prevalence
of Neisseria gonorrhoeae (12.5% versus 8.8%; P = 0.64),
and prevalence of Syphilis (25.0% versus 26.8%; P = 1.0).
However, the diﬀerence in the prevalence of Chlamydia
trachomatiswasborderline(35.7%versus13.5%;P = 0.058).
Thestatisticalpowerfortheseanalysesmayhavebeenlimited
due to the small samples sizes.6 Infectious Diseases in Obstetrics and Gynecology
4. Discussion
While the burden of disease associated with HIV and HPV
infection is signiﬁcant, especially in sub-Saharan Africa,
there is limited research on the link between HPV and HIV
acquisition. In the present study, we found that HR-HPV
was signiﬁcantly and independently associated with HIV
acquisition among South African FSWs and that the risk of
HIV infection signiﬁcantly increased in the event of multiple
HR-HPVinfections.NoassociationwasfoundwithLR-HPV.
Toourknowledge,onlysixpublishedobservationalstud-
ies, three conducted among men and three among women,
have explored HPV infection and HIV acquisition [28–
30, 37–39] .A l lb u to n es t u d y[ 38]w e r ec o n d u c t e di ns u b -
Saharan Africa, where HIV transmission is predominantly
heterosexual. In ﬁve of these studies, HIV seroconversion
was associated with HR-HPV. Only two studies found an
association between LR-HPV and HIV acquisition.
One study [38], in which did HPV was not assessed by
type, reported that anal HPV infection was associated with
HIV acquisition among men who have sex with men (aHR =
3.5, 95% CI: 1.2–10.6). Another study [37] found that HIV
acquisition was facilitated among HR-HPV infected South
African men (adjusted incidence rate ratio= 3.8, 95% CI:
1.8–7.7), but not among those infected with LR-HPV. A
third study conducted among Kenyan men [39]r e p o r t e da n
independent, increased risk of HIV seroconversion among
HPV-positive men (aHR = 1.8, 95% CI: 1.1–2.9) but not
when HR and LR-HPV were assessed separately. Among
w o m e n ,ac a s e - c o n t r o ls t u d y[ 30] reported that for Zim-
babwean women with cervical HPV infection, the odds of
acquiring HIV were over twice higher than among HR-
HPV and LR-HPV uninfected women after adjustment for
behavioural and biological factors (aOR = 2.3, 95% CI:
1.4–3.9 and aOR = 2.8, 95% CI: 1.3–5.9, resp.). Another
studyconductedinZimbabwe[28]indicatedthatconcurrent
genital HR-HPV (assessed at the time of HIV detection)
and recent HR-HPV infection (assessed within six months
of HIV detection) approximately doubled the risk of HIV
acquisition independently of sexual risk factors and other
STIs (aHR = 2.0, 95% CI: 1.2–3.3 and aHR = 2.0, 95% CI:
1.2–3.2,resp.).Thisstudyalsofoundasigniﬁcantassociation
between concurrent LR-HPV infection and HIV acquisition
(aHR = 1.7, 95% CI: 1.0–2.9). Lastly, the cohort study
conducted among Rwandan FSWs [29] found that women
who HIV seroconverted were about ﬁve times more likely to
have been infected with HR-HPV at baseline (OR = 4.9, 95%
CI: 1.2–19.7).
Our study ﬁndings are mostly coherent with these
reports; however, comparisons are diﬃcult because of sub-
stantial variations in terms of sample population, covariate
adjustment and HPV status assessment. For instance, only
one study assessed the association among individuals with
risky sexual behaviour [29] but reported unadjusted esti-
mates. The other ﬁve studies [28, 30, 37–39] controlled for
HSV-2 infection but only three [28, 30, 37] for condom use
andanotherthreeforotherSTIsstatus[28,30,38].Themost
notable variations concerned the timing of HPV-infection
status assessment, which varied from baseline [28, 38, 39],
to six months after recruitment [29], within three [30]o r
six months [28] before HIV seroconversion, concurrently
with HIV detection [28] or after HIV seroconversion [37].
Due the transient nature of HPV infections, it is plausible
that the association between HPV and HIV acquisition is
time dependent, and it could explain the variations in study
ﬁndings. Diﬀering study designs may also explain the fact
that we did not detect an increased risk of HIV acquisition
with LR-HPV infection, as it had been reported by two of the
studies [28, 30], but it could also reﬂect speciﬁc HPV-type
diﬀerences in host response.
Several nonexclusive and plausible explanations can
account for our ﬁndings. Firstly, HIV and HPV are sexually
transmitted viruses which share the same transmission
route and behavioral risk factors. However, the association
observedremainslargelysigniﬁcantevenaftercontrollingfor
sexual behavioral covariates although residual confounding
cannot be excluded. Secondly, it could be argued that HIV-
HPV coinfected male partners may have shed HR-HPV
more intensively than HIV-negative male partners. Indeed,
in the case of a depressed immune system, HPV lesions are
more likely to be dysplastic [40], and immunodepression
can reactivate latent HPV infections [41–43]. Since HPV is
assumed to be more infectious than HIV, it is possible that
women exposed to both infections at the same time acquire
HPV before HIV, and that the hypothesized eﬀect of HPV
infectiononHIVacquisitionbeduetoresidualconfounding.
This would be an issue even if the ascertainment of HPV
among exposed partners occurred before HIV seroconver-
sion. Thirdly, the ﬁndings could simply indicate that HR-
HPV facilitates HIV acquisition, which seems the most likely
explanation, since no eﬀect of LR-HPV was detected. Lastly,
as in any statistical analysis, our results could be due to
chance. However, the numbers of HR and LR infections
are similar. Thus, the powers of the individual analyses of
the eﬀect of HR- and LR-HPV on HIV acquisition are also
similar. The probability that our results are due to chance
cannot be excluded, but we think that it is reasonably small.
Several factors could account for a causal association
of HR-HPV with HIV acquisition. ﬁrst, their association is
very strong, as shown in observational studies. Secondly,
causality is biologically plausible: HPV could disrupt the
local and systemic immune systems and predispose to HIV
infection [27], either via the recruitment of HIV target cells
[44, 45], which would facilitates its acquisition, or cytokine
stimulation [45, 46], which could increase HIV replication.
Thus, since HR-HPV and LR-HPV are believed to elicit
ad i ﬀerential immune response [47], it would explain the
lack of association between LR-HPV and HIV as found
in this study and in a cross-sectional survey conducted in
Zambia [16]. Thirdly, HPV could lead to genital lesions that
may facilitate HIV acquisition. Unfortunately, we did not
have the necessary data on HPV-associated lesions to assess
this hypothesis. Further research is needed to clarify the
etiological mechanisms of the association between HPV and
HIV incidence.
This study has several limitations: First, its observational
nature does not allow the interpretation of the ﬁndings
as a causal association between HR-HPV status and HIVInfectious Diseases in Obstetrics and Gynecology 7
acquisition. Secondly, we did not obtain sets of samples
collected at the same time for all participants although only
a small proportion were not included because of missing
data. Thirdly, HSV-2 status, anal HPV sampling, and cervical
cytology were not available, and thus their eﬀects on the
observed association could not be tested. In particular,
HSV-2 has been hypothesized to facilitate HIV acquisition
[48], and could potentially play a mediating role. However,
among the six identiﬁed studies exploring the link between
HPV and HIV seroconversion, ﬁve [28, 30, 37–39]f o u n da
signiﬁcant association even when HSV-2 status was included
as a covariate. Fourthly, HPV infections are known to be
transient [49], and this may have diluted the associations
observed in this study. Lastly, the sample of women used
in this study was not a representative sample. Nevertheless,
there are few reasons to think that these limitations could
invalidate the observed association between HR-HPV status
and HIV acquisition.
5. Conclusion
Despite these limitations, these ﬁndings indicate that the
hypothesis of a facilitating eﬀe c to fH R - H P Vo nH I Va c q u i -
sition requires further investigation using longitudinal data.
The validation of this hypothesis could necessitate testing the
potential protective eﬀect of available HPV vaccines on HIV
acquisition.
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